Emerging therapies for glioblastoma: current state and future directions
L Rong, N Li, Z Zhang - Journal of Experimental & Clinical Cancer …, 2022 - Springer
Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …
extremely poor prognosis. Given the poor survival with currently approved treatments for …
A review of glioblastoma immunotherapy
Introduction Glioblastoma is a very aggressive cancer with dismal prognosis despite
standard of care including surgical resection, radiation therapy, and chemotherapy. There is …
standard of care including surgical resection, radiation therapy, and chemotherapy. There is …
Advancing to the era of cancer immunotherapy
Y Wang, M Wang, HX Wu, RH Xu - Cancer Communications, 2021 - Wiley Online Library
Cancer greatly affects the quality of life of humans worldwide and the number of patients
suffering from it is continuously increasing. Over the last century, numerous treatments have …
suffering from it is continuously increasing. Over the last century, numerous treatments have …
Risks from deferring treatment for genitourinary cancers: a collaborative review to aid triage and management during the COVID-19 pandemic
Context The coronavirus disease 2019 (COVID-19) pandemic is leading to delays in the
treatment of many urologic cancers. Objective To provide a contemporary picture of the risks …
treatment of many urologic cancers. Objective To provide a contemporary picture of the risks …
Advances in glioblastoma therapy: an update on current approaches
Glioblastoma multiforme (GBM) is a primary malignant brain tumor characterized by a high
grade of malignancy and an extremely unfavorable prognosis. The current efficacy of …
grade of malignancy and an extremely unfavorable prognosis. The current efficacy of …
[HTML][HTML] Challenges in lung cancer therapy during the COVID-19 pandemic
Coronavirus disease 2019 (COVID-19), caused by the newly identified strain of the
coronavirus family severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has …
coronavirus family severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has …
[HTML][HTML] Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non–small cell lung cancer
BC Tong, L Gu, X Wang, DA Wigle, JD Phillips… - The Journal of Thoracic …, 2022 - Elsevier
Objectives Pembrolizumab is a programmed death receptor-1 masking antibody approved
for metastatic non–small cell lung cancer. This Phase 2 study (NCT02818920) of …
for metastatic non–small cell lung cancer. This Phase 2 study (NCT02818920) of …
Nivolumab for patients with high-risk oral leukoplakia: A nonrandomized controlled trial
Importance Proliferative verrucous leukoplakia (PVL) is an aggressive oral precancerous
disease characterized by a high risk of transformation to invasive oral squamous cell …
disease characterized by a high risk of transformation to invasive oral squamous cell …
Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease: a cohort study
MK van der Kooij, KPM Suijkerbuijk… - Annals of internal …, 2021 - acpjournals.org
Background: Because immune checkpoint inhibition (ICI) can cause immune-related
adverse events (irAEs) mimicking immunologic diseases, patients with preexisting …
adverse events (irAEs) mimicking immunologic diseases, patients with preexisting …
Association between age and survival trends in advanced non–small cell lung cancer after adoption of immunotherapy
T Voruganti, PR Soulos, R Mamtani, CJ Presley… - JAMA …, 2023 - jamanetwork.com
Importance The introduction of immune checkpoint inhibitors (ICIs) has transformed the care
of advanced non–small cell lung cancer (NSCLC). Although clinical trials suggest …
of advanced non–small cell lung cancer (NSCLC). Although clinical trials suggest …